TITLE

Molecular chaperones as targets to circumvent the CFTR defect in cystic fibrosis

AUTHOR(S)
Chanoux, Rebecca A.; Rubenstein, Ronald C.
PUB. DATE
July 2012
SOURCE
Frontiers in Pharmacology;Jul2012, Vol. 3, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
88094008

 

Related Articles

  • Calcium-pump inhibitors induce functional surface expression of ΔF508-CFTR protein in cystic fibrosis epithelial cells. Egan, Marie E.; Glöckner-Pagel, Judith; Ambrose, Catherine A.; Cahill, Paula A.; Pappoe, Lamiko; Balamuth, Naomi; Cho, Edward; Canny, Susan; Wagner, Carsten A.; Geibel, John; Caplan, Michael J. // Nature Medicine;May2002, Vol. 8 Issue 5, p485 

    The most common mutation in cystic fibrosis, ΔF508, results in a cystic fibrosis transmembrane conductance regulator (CFTR) protein that is retained in the endoplasmic reticulum (ER). Retention is dependent upon chaperone proteins, many of which require Ca++ for optimal activity. Interfering...

  • CFTR Molecular Analysis Reveals Infrequent Allele Frequencies in Nine Cystic Fibrosis Patients from São Paulo State, Brazil. Goloni-Bertollo, Eny Maria; Rossit, Andréa Regina B.; Batista, Jaõo; Junior, Salomão; Fett-Conte, Agnes Cristina; Raskin, Salmo // Human Biology;Jun2003, Vol. 75 Issue 3, p393 

    Studies the CFTR gene mutation in patients with cystic fibrosis in Sao Paulo, Brazil. Frequencies of cystic fibrosis mutations; Molecular and clinical characteristics of patients with cystic fibrosis.

  • Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype. Clancy, J P; Johnson, S G; Yee, S W; McDonagh, E M; Caudle, K E; Klein, T E; Cannavo, M; Giacomini, K M // Clinical Pharmacology & Therapeutics;Jun2014, Vol. 95 Issue 6, p592 

    Cystic fibrosis (CF) is a life-shortening disease arising as a consequence of mutations within the CFTR gene. Novel therapeutics for CF are emerging that target CF transmembrane conductance regulator protein (CFTR) defects resulting from specific CFTR variants. Ivacaftor is a drug that...

  • Mechanism-based corrector combination restores ΔF508-CFTR folding and function. Okiyoneda, Tsukasa; Veit, Guido; Dekkers, Johanna F; Bagdany, Miklos; Soya, Naoto; Xu, Haijin; Roldan, Ariel; Verkman, Alan S; Kurth, Mark; Simon, Agnes; Hegedus, Tamas; Beekman, Jeffrey M; Lukacs, Gergely L // Nature Chemical Biology;Jul2013, Vol. 9 Issue 7, p444 

    The most common cystic fibrosis mutation, ΔF508 in nucleotide binding domain 1 (NBD1), impairs cystic fibrosis transmembrane conductance regulator (CFTR)-coupled domain folding, plasma membrane expression, function and stability. VX-809, a promising investigational corrector of...

  • Cystic fibrosis gene mutations: evaluation and assessment of disease severity. Vallières, Emilie; Elborn, Joseph Stuart // Advances in Genomics & Genetics;2014, Vol. 4, p161 

    The cystic fibrosis transmembrane regulator (CFTR) gene encodes an ion channel transporter, the CFTR protein. Since its identification in 1989, more than 1,900 sequence variants have been reported, resulting in a wide spectrum of clinical phenotypes. Cystic fibrosis (CF) is associated with many...

  • Inflammation and CFTR: might neutrophils be the key in cystic fibrosis? Witko-Sarsat, V.; Sermet-Gaudelus, I.; Lenoir, G.; Descamps-Latscha, B. // Mediators of Inflammation;Feb99, Vol. 8 Issue 1, p7 

    THE aim of this hypothesis is to provide new insights into the still unclear mechanisms governing airway inflammation in cystic fibrosis. Although the genetic basis of cystic fibrosis as well as the molecular structure of cystic fibrosis transmembrane regulator (CFTR), the mutated protein which...

  • Activation of the epithelial Na+ channel (ENaC) requires CFTR CI- channel function. Reddy; Light, M.M. // Nature;11/18/1999, Vol. 402 Issue 6759, p301 

    Examines the ion channel regulation in the genetic disease cystic fibrosis. Dependence of epithelial Na+ channel on CFTR activity; Primary defect in Cl- channel permeability in cystic fibrosis; Factors in the reduced salt absorption in cystic fibrosis.

  • The Hsc70 co-chaperone CHIP targets immature CFTR for proteasomal degradation. Meacham, Geoffrey C.; Patterson, Cam; Zhang, Wenyue; Younger, J. Michael; Cyr, Douglas M. // Nature Cell Biology;Jan2001, Vol. 3 Issue 1, p100 

    The folding of both wild-type and mutant forms of the cystic-fibrosis transmembrane-conductance regulator (CFTR), a plasma-membrane chloride-ion channel, is inefficient. Most nascent CFTR is retained in the endoplasmic reticulum and degraded by the ubiquitin proteasome pathway. Aberrant folding...

  • Targeted therapies to improve CFTR function in cystic fibrosis. Brodlie, Malcolm; Haq, Iram J.; Roberts, Katie; Elborn, J. Stuart // Genome Medicine;9/25/2015, Vol. 7 Issue 1, p1 

    Cystic fibrosis is the most common genetically determined, life-limiting disorder in populations of European ancestry. The genetic basis of cystic fibrosis is well established to be mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that codes for an apical membrane...

  • Current insights into the role of PKA phosphorylation in CFTR channel activity and the pharmacological rescue of cystic fibrosis disease-causing mutants. Chin, Stephanie; Hung, Maurita; Bear, Christine // Cellular & Molecular Life Sciences;Jan2017, Vol. 74 Issue 1, p57 

    Cystic fibrosis transmembrane conductance regulator (CFTR) channel gating is predominantly regulated by protein kinase A (PKA)-dependent phosphorylation. In addition to regulating CFTR channel activity, PKA phosphorylation is also involved in enhancing CFTR trafficking and mediating...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics